1 Identification of therapeutic targets for 18 clinical diseases by integrating human plasma proteome with genome 2

3 Shifang Li, Meijiao Gong

Laboratory of Immunology and Vaccinology, FARAH, ULiège, Liège 4000, Belgium. 4

- Correspondence: 5
- 6 Shifang Li, fruceslee@gmail.com

Laboratory of Immunology and Vaccinology, FARAH, ULiège, Liège 4000, Belgium 7

8 Abstract

9 The proteome is an abundant source of potential therapeutic targets, and a comprehensive evaluation of proteins as therapeutic targets for a wide range of 10 diseases is required. By screening 4,907 plasma proteins, we conducted a 11 12 systematically two-sample proteome-wide Mendelian randomisation (MR) study to 13 uncover potential therapeutic targets for 18 clinical diseases. Following MR analysis and stringent process filtering, a total of 146 causative plasma proteins (false 14 discovery rate<0.05) were discovered. Colocalization analysis (Posterior Probability 15 16 H4>0.8) further supported the causality of three proteins (MAP2K1, GFRA1, and THBS3) in gastroesophageal reflux disease; LYPLAL1 in keratoconus; three proteins 17 (PCSK9, ANGPTL4, and GCKR) in familial hyperlipidemia; CRAT in atopic eczema; 18 three proteins (IRF3, CA12, and TNFRSF1B) in hypothyroidism; AIF1 in age-related 19 20 hearing impairment; SCARF2 in male pattern baldness; IRF3 in basal cell carcinoma; and four proteins (RPS6KA1, ULK3, MPPED2, and BTN3A1) in prostate cancer. 21 22 Interestingly, having a genetically higher circulating CA12 level is associated with a lower risk of hypothyroidism (OR=0.47, p-value=1.68e-05, Posterior Probability 23 24 H4=0.82). Single-cell RNA sequencing analysis showed that CA12 was mainly expressed in fibroblasts and epithelial cells in patient thyroid tissue and that its 25 expression increased in older adults. Furthermore, with a proportion of 3.8%, 26 hypothyroidism appears to mediate the effect of IRF3 on idiopathic pulmonary 27 28 fibrosis, according to mediation analysis. Overall, our research could provide new 29 insights into the etiology of clinical diseases as well as intriguing targets for the TE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. development of screening biomarkers and therapeutic treatments. 30

31 Introduction

Plasma proteins are involved in numerous essential physiological processes, such 32 33 as immunomodulation, substance transport, signaling, and homeostasis maintenance, and their dysregulation has been frequently reported in a variety of diseases, implying 34 that these dysregulated proteins are involved in disease pathogenesis [1-2]. Given the 35 importance of plasma proteins in disease and the fact that plasma proteins are a 36 primary source of therapeutic targets, identifying disease-related plasma proteins can 37 38 assist in deciphering disease pathophysiology and providing possible molecular targets for drug development [3-4]. Currently, large-scale proteomics study have 39 uncovered over 18,000 protein quantitative trait loci (pOTLs) spanning over 4,800 40 proteins, including over 1,800 independent cis-pQTLs [5]. Through Mendelian 41 42 randomisation (MR), these studies provide a significant data resource for systematically understanding the causal impact of plasma proteins on clinical 43 disease. Normally, MR employs naturally randomized genetic diversity at the moment 44 of conception as a natural experiment to uncover the causal relationship between 45 46 exposure and disease, reducing the risk of reverse causation and confounding bias [6]. Proteome-wide MR has currently revealed important insights into the etiology of 47 stroke, idiopathic pulmonary fibrosis (IPF), and COVID-19, as well as the 48 prioritization of therapeutic targets [7-9]. Indeed, drugs containing human genetic 49 evidence are more likely to succeed in Phase II and Phase III trials, with human 50 genetic data supporting two-thirds of FDA-approved drugs in 2021 [10-12]. 51

In this study, we utilized proteome-wide MR to identify circulating protein biomarkers linked with 18 clinical traits by integrating the human plasma proteome with genetic data. Colocalization analyses are conducted to determine the robustness of the proteins' instrumental variables. Furthermore, we performed single-cell sequencing data analysis and mediation analysis to identify the enriched cell types of candidate proteins in tissues as well as the potential mechanisms mediated between diseases, respectively.

59 Methods

60 **Proteomic data source**

61 A large-scale protein quantitative trait loci (pOTL) study in 35,559 Icelanders yielded the largest and most thorough genome-wide association studies (GWAS) 62 63 summary datasets on 4,907 circulating proteins [5]. The detailed description of the datasets can be found in the original study [5]. In brief, the plasma protein levels were 64 determined using the SomaScan version 4 assay from SomaLogic, and the pQTL 65 datasets were made up of associations between genome-wide genetic variations and 66 plasma proteins that were adjusted for age and gender using the BOLT-LMM linear 67 mixed model. As instrumental variables in the following MR analysis, genome-wide 68 significant and independent single nucleotide polymorphisms (SNPs) with 69 *p*-value<5e-08 and r²<0.001 of pQTLs were employed. 70

71 18 clinical traits data sources

72 To identify the potential therapeutic targets, the GWAS summary statistics from 18 diseases, including male pattern baldness (ID: GCST006661, 36,166 cases and 73 16,708 controls), gastroesophageal reflux disease (71,522 cases and 261,079 controls), 74 keratoconus (ID: GCST90013442, 2,116 cases and 24,626 controls), selective IgA 75 76 deficiency disease (ID: GCST003814, 1,635 cases and 4,852 controls), fibromuscular dysplasia (ID: GCST90026612, 1,556 cases and 7,100 controls), age-related hearing 77 impairment (ID: GCST90012115, 125,688 cases and 205,071 controls), familial 78 hyperlipidemia (ID: GCST90104003, 3,838 cases and 345,384 controls), atopic 79 eczema (ID: GCST90027161, 22,474 cases and 774,187 controls), Brugada syndrome 80 (ID: GCST90086158, 2,820 cases and 10,001 controls), cataract (ID: GCST009963, 81 21,679 cases and 387,283 controls), uterine fibroid (ID: GCST009158, 20,406 cases 82 and 223,918 controls), amyotrophic lateral sclerosis (ID: GCST90027164, 27,205 83 84 cases and 110,881 controls), acne (ID: GCST90245818, 34,422 cases and 364,991 controls), posterior urethral valve (ID: GCST90134327, 756 cases and 4,823 controls), 85 hypothyroidism (ID: GCST90204167, 51,194 cases and 443,383 controls), prostate 86 cancer (ID: GCST90274714, 122,188 cases and 604,640 controls), basal cell 87 carcinoma (ID: GCST90013410, 17,416 cases and 375,455 controls), and unipolar 88 89 depression (ID: GCST006477, 66,809 individuals) were retrieved from the GWAS Catalog (https://www.ebi.ac.uk/gwas/) when an ID was provided (Supplementary 90

Table 1). To the best of our knowledge, the exposure sample dataset (4,907 proteomic 91 92 data) did not overlap with the outcome (18 clinical traits) we selected. Further information on the outcome dataset is listed in Supplementary Table 1. If standard 93 error and effect size are missing but z-scores are included in the GWAS summary 94 statistics file, effect size and standard error can be calculated as follows: 95

$$effect \ size = \frac{z}{\sqrt{2 * p(1-p) * (n+z^2)}}$$
$$standard \ error = \frac{1}{\sqrt{2 * p(1-p) * (n+z^2)}}$$

where n is the number of individuals used in the association study and p is the 96 *p*-value for the association study. 97

98

Mendelian randomisation analysis

99 Based on the presence of non-overlapping samples between exposure (4,907 proteome data) and outcome (18 clinical traits), two-sample MR analysis has been 100 performed using the TwoSampleMR, as previously described [13-14]. In brief, the 101 data were harmonized after clumping (r²<0.001) to exclude ambiguous SNPs with 102 103 non-concordant alleles and palindromic SNPs. Following that, the Wald ratio method was used to generate effect estimates when considering a plasma protein instrumented 104 by a single SNP, and the Inverse Variance Weighted (IVW) method was employed for 105 proteins instrumented by two or more SNPs, followed by heterogeneity analysis. To 106 107 test the consistency of the associations, additional methods such as simple mode, weighted mode, weighted median, and MR-Egger were applied. The MR-Egger 108 intercept test was used to detect probable unbalanced pleiotropy (horizontal 109 110 pleiotropy). The PhenoScanner (http://www.phenoscanner.medschl.cam.ac.uk/) 111 databases were utilized to investigate whether variants had possible pleiotropic associations with other diseases or traits when fewer than three genetic instrumental 112 113 factors were employed in MR analysis. Associations with p-value<5e-08 were deemed significant. In a heterogeneity test, we calculated I² statistics with the "Isq()" 114 function and heterogeneity *p*-value with the "mr heterogeneity()" function; results 115 with an I^{2} 50% and a heterogeneity *p*-value (Q pval<0.05) were considered 116

heterogeneous (substantial heterogeneity) [8]. The F-statistic was calculated to 117 quantify instrument strength, and an F-statistic greater than 10 indicated an adequately 118 powerful instrument. To account for multiple tests, the Benjamini-Hochberg 119 correction, which governs the false discovery rate (FDR), was implemented. The 120 association with a *p*-value of 0.05 but a Benjamini-Hochberg adjusted *p*-value greater 121 than 0.05 was considered nominally significant, while the association with a 122 Benjamini-Hochberg adjusted *p*-value greater than 0.05 was considered significant. 123 124 Furthermore, the Steiger filtering approach was used to verify the validity of the causal direction between the hypothesized exposure and outcomes using the 125 directionality test() function in the "TwoSampleMR" package [14]. In addition, we 126 performed a leave-one-out analysis to examine whether the MR estimates could be 127 explained by a single SNP (removing estimates where all but one leave-one-out 128 configuration had a *p*-value<0.05). Only MR results that met all of the following 129 criteria were chosen to avoid complex causation relationships: (1) MR-Egger 130 regression revealed no pleiotropy (p-value>0.05); (2) true causal direction and Steiger 131 132 *p*-value<0.05; (3) heterogeneity test $I^2 < 0.5$; (4) leave-one-out analysis MR *p*-value<0.05 after removing outliers; and (5) FDR<0.05. 133

134 Colocalization Analysis

Colocalization analysis was executed to figure out whether the protein and 135 diseases shared the same causative genetic variations and to rule out confounding 136 owing to linkage disequilibrium (LD). This was performed using the "coloc" R 137 package [15]. The following five mutually exclusive hypotheses were tested: (1) 138 Neither protein nor disease has a causal SNP (H0); (2) only protein has a causal SNP 139 140 (H1); (3) only disease has a causal SNP (H2); (4) both protein and disease have a causal SNP, but the two causal SNPs differ (H3); and (5) both protein and disease 141 have a causal SNP and share the same SNP (H4). To measure the support for each 142 hypothesis, the posterior probability was adopted. A posterior probability for H4 (PH4) 143 of more than 80% was regarded as significant evidence of colocalization. 144

145 Single-cell RNA sequencing analysis

146

Single-cell RNA-sequencing of 54,762 cells taken from normal thyroid tissue

from 7 individuals who had thyroidectomy and had verified instances of differentiated 147 thyroid carcinoma were retrieved from Expression Omnibus 148 Gene (https://www.ncbi.nlm.nih.gov/geo/, GSE182416) [16]. Seurat 4.2.0 was used for 149 processing and analyzing the single-cell dataset, as previously stated [13]. In short, 150 low-quality cells by selecting feature numbers ranging from 200 to 3,000 were 151 excluded. The data were normalized using the "LogNormalize" method using the 152 "NormalizeData" function. The "vst" selection method in the "FindVariableFeatures" 153 154 function yielded a total of 2,000 highly variable genes for each sample. The "FindIntegrationAnchors" function was utilized to correct the batch effect and merged 155 the 7 patients for further analysis. The k-nearest neighbors were determined using 156 principal component analysis (PCA). For data visualization, the dimension reduction 157 approach UMAP (Uniform Manifold Approximation and Projection) was utilized. 158 Cell type annotation was carried out in their study based on the specific gene 159 expression [16]. 160

161 Mediation analysis

162 The product of coefficients approach was employed to quantify the impacts of proteins on IPF outcomes via hypothyroidism for proteins that causally are associated 163 with IPF and hypothyroidism, as mentioned by Yoshiji and her colleagues [8]. In brief, 164 the effect of IRF3 on hyperthyroidism was first evaluated and then multiplied by the 165 effect of hyperthyroidism on IPF. Following that, the proportion of the entire effect of 166 IRF3 on IPF mediated by hyperthyroidism was calculated by dividing the 167 hyperthyroidism-mediated effect (hyperthyroidism-to-IPF) by the overall effect 168 (IRF3-to-IPF) [8,17]. 169

170 **Results and discussion**

171 Identification of causal proteins associated with clinical traits

The MR analysis was used to evaluate the causal effects of 4,907 plasma proteins on 18 diseases by using *cis*-pQTLs (pQTLs that reside within a 1 Mb region around a transcription start site of a protein-coding gene) for these proteins as instrumental variables and 18 clinical traits as outcomes (**Figure 1A** and **Supplemental Table 1**). Given that *cis*-pQTLs are more likely than *trans*-pQTLs to directly alter the

transcription or translation of their linked gene, the likelihood of directional horizontal 177 pleiotropy is considerably reduced [8]. Following MR analysis and stringent process 178 filtering (Method and Figure 1A), a total of 146 plasma proteins were found for 179 associations with 18 clinical traits (Figure 1B and Supplemental Table 1). 180 Particularly, the causal associations were found for 12 clinical traits, including male 181 pattern baldness (6 proteins), gastroesophageal reflux disease (15 proteins), 182 Keratoconus (3 proteins), selective IgA deficiency disease (2 proteins), age-related 183 184 hearing impairment (12 proteins), familial hyperlipidemia (8 proteins), atopic eczema (4 proteins), Brugada syndrome (1 protein), amyotrophic lateral sclerosis (1 protein), 185 hypothyroidism (27 proteins), basal cell carcinoma (5 proteins), and prostate cancer 186 (62 proteins). For example, a genetic tendency to elevated LYPLAL1 was linked to an 187 increased risk of keratoconus (OR per-1-SD higher plasma protein level [95% 188 confidence interval (CI)]=2.52[1.56, 4.06]; p-value=0.00014). Higher levels of 189 genetically predicted CRAT were linked to an increased incidence of atopic eczema 190 (OR[95% CI]=1.63[1.27, 2.10]; p-value=0.00012). Genetically determined higher 191 192 SCARF2 levels were associated with a higher risk of male pattern baldness (OR[95%CI]: 1.23[1.11, 1.36]; p-value=3.91e-05). It is worth noting that the 193 causative protein that is significantly linked to one clinical trait may also be linked to 194 other clinical traits, while this is nominally significant (Figure 1B). For example, 195 196 THBS3, which was associated with an increased risk of gastroesophageal reflux disease (OR[95%CI]=1.31[1.15, 1.49]; p-value=6.2e-05), was also linked to a higher 197 risk of cataract (OR[95%CI]=1.014[1.003, 1.025]; p-value=0.0125) and uterine 198 fibroid (OR[95%CI]=1.32[1.05, 1.67]; p-value=0.016). Furthermore, CRAT, which 199 200 was linked to atopic eczema, was also associated with a higher risk of age-related hearing impairment (OR[95%CI]=1.079[1.022, 1.139]; p-value=0.0059) 201 and fibromuscular dysplasia (OR[95%CI]=3.28[1.11,9.71]; p-value=0.031). These 202 findings indicated an opportunity for existing pharmaceutical repurposing in the 203 prevention of disease. In fact, inhibitors of interleukin-23 (IL-23) signaling, initially 204 developed for psoriasis, have been repurposed for Crohn's disease based on GWAS 205 that found links between genetic variants in the IL23R gene and Crohn's disease 206

207 [3,18,19]. Similarly, IL-17A signaling inhibitors established for psoriasis, rheumatoid arthritis, and uveitis have been investigated and approved for ankylosing spondylitis 208 based on GWAS findings [3]. Notably, LYPLAL1, which has been connected to an 209 increased risk of keratoconus, has also been linked to a lower risk of male pattern 210 baldness (OR[95%CI]=0.87[0.77, 0.995]; p-value=0.043) and atopic eczema 211 (OR[95%CI]=0.74[0.60, 0.92]; p-value=0.0062). These findings suggested that when 212 repurposing drugs, it is essential to consider the potential effects caused by 213 214 multiplicity.

Colocalization analysis was then implemented to determine whether previously 215 identified relationships between proteins and clinical traits were driven by linkage 216 disequilibrium (LD) (Figure 1C). Among the 146 causative proteins, 18 showed 217 218 higher colocalization evidence (posterior probability PH4>0.8), whereas 6 showed medium colocalization evidence (posterior probability PH4>0.7) (Figure 1D). For 219 example, the colocalization indicated that the genetic variations linked to CRAT, 220 LYPLAL1, and THBS3 (cis-pOTLs) were caused by the same genetic variants that 221 222 underpin the association with individual clinical traits (Figure 1E). For the other 122 causative proteins, there was no colocalization evidence (posterior probability 223 PH4<0.6), indicating that the MR findings for these proteins were likely biased by 224 LD. 225

Genetically increased circulating CA12 level is associated with a reduced risk of hypothyroidism

Based on the MR and colocalization analysis results, the causative protein related 228 to the clinical traits was sought to further examine the role they played. In the case of 229 230 hypothyroidism, among the three causative proteins, a one standard deviation rise in genetically predicted CA12 levels was linked with a lower risk of hypothyroidism 231 (OR=0.47, 95%CI 0.33-0.66, p-value=1.68e-05) (Figure 1B, Figure 2A and 232 **Supplementary Tables 1**). To confirm the premise of a lack of directional pleiotropy, 233 reintroduce confounding, 234 which can we used PhenoScanner (http://www.phenoscanner.medschl.cam.ac.uk/) to find out whether the CA12 235 cis-pQTLs were related to any characteristics or diseases at the genome-wide 236

significant threshold of *p*-value<5e-08. The deCODE study's primary *cis*-pOTL for 237 CA12 (rs7183733) was linked to dentures (Supplementary Tables 1). Indeed, 238 employing CA12 cis-pQTL as exposure and dentures as outcomes, MR analysis 239 revealed that CA12 levels were expected to impact dentures (OR=1.12, 95%CI 240 1.08-1.16, p-value=5.59e-12) with no reverse causation (p-value=1.83e-04, 241 MR-Steiger test). This finding implies that the association between CA12 and 242 dentures is a case of vertical pleiotropy, which does not contradict MR explanation. 243 244 GTEx v8 (https://gtexportal.org/), which contains expression data from 49 tissues and 838 individuals, was used to investigate the tissues in which CA12 is expressed. 245 When compared to whole blood, CA12 was highly expressed in numerous tissues, 246 including the thyroid (*p*-value<0.001) (Figure 2B). To better understand the cell type 247 of origin of CA12, we examined single-cell CA12 expression in human thyroid 248 tissues from thyroidectomy 249 patients (GSE182416, available at https://www.ncbi.nlm.nih.gov/geo/) [16]. CA12 was highly enriched in thyroid 250 epithelial cells and fibroblasts in single-cell sequencing as compared to other cell 251 252 types in adipose tissues (p-value<0.001) (Figure 2C). No difference in expression between epithelial cells and fibroblasts was found (p-value>0.05). These findings 253 suggested that certain cell types may be accountable for local CA12 production in 254 these tissues. Furthermore, we noticed that CA12 was considerably more expressed in 255 older persons (p-value<0.001) (Figure 2D), who had a greater prevalence and 256 incidence of hypothyroidism than young ones [20]. Taken together, these findings 257 imply that CA12 may be an appropriate target for hypothyroidism. 258

In fact, the causative protein found in the study might be utilized to infer disease 259 mediator associations [7]. As an example, recent research has shown that 260 hypothyroidism has a positive causal effect on IPF [21]; however, the mechanisms 261 underlying this association are not well understood. To evaluate the indirect effect of 262 proteins on IPF outcomes via hypothyroidism, we performed a mediation analysis 263 utilizing the effect estimates from two-step MR and the overall effect from primary 264 MR. To accomplish this, the largest GWAS of IPF (2,668 cases and 8,591 controls) 265 was extracted from a recent study [22] and three proteins (IRF3, CA12, and 266

TNFRSF1B) that have a causal effect on hypothyroidism were initially used to identify a causal effect on IPF using MR analysis, as described above. Surprisingly, only IRF3 was found to have a causal effect on IPF (*p*-value<0.05/3=0.016, Bonferroni-adjusted for three proteins) (OR=2.79, 95%CI 1.29-6.02, *p*-value=0.0088) (**Figure 2E** and **Supplementary Tables 1**). Following that, the product of coefficients method was utilized to assess the mediation effect, and 3.8% of the IRF3 mediation affect on IPF via hypothyroidism was uncovered (**Figure 2F**).

Overall, our analysis identified 18 putative causative proteins for clinical traits by integrating proteogenomics research. More research is needed to determine the viability of the 18 discovered proteins as therapeutic targets for clinical disease therapy. Furthermore, the detailed mechanism by which these proteins alter clinical traits should be explored in depth using a multi-omics approach.

279 Competing interests

280 None declared.

281 Author contributions

282 Conception and design: SF. Data analyses: SF. Manuscript writing: SF. Data
283 acquisition: SF and MJ.

284 Acknowledgments

We would like to thank the IPF GWAS Collaborative Group for providing us with the IPF GWAS summary data. The authors would also like to thank the other researchers who contributed to developing the GWAS datasets utilized in this work for making them available for research purposes.

289 **References**

- Henning RH & Brundel BJJM. Proteostasis in cardiac health and disease. *Nat Rev Cardiol.* 2017;14:637-53. doi:10.1038/nrcardio.2017.89.
- Walker KA, Chen J, Shi L, et al. Proteomics analysis of plasma from middle-aged
 adults identifies protein markers of dementia risk in later life. *Sci Transl Med*. 2023,
 15, eadf5681. doi:10.1126/scitranslmed.adf5681.
- 2953Trajanoska K, Bhérer C, Taliun D, et al. From target discovery to clinical drug296developmentwithhumangenetics.Nature.2023;620:737–45.

doi:10.1038/s41586-023-06388-8.

Wallentin L, Eriksson N, Olszowka M, et al. Plasma proteins associated with
cardiovascular death in patients with chronic coronary heart disease: A retrospective
study. *PLoS Med* 2021;18:1-22. doi:10.1371/journal.pmed.1003513.

5 Ferkingstad E, Sulem P, Atlason BA, et al. Large-scale integration of the plasma
proteome with genetics and disease. *Nat Genet* 2021;53:1712-21.
doi:10.1038/s41588-021-00978-w.

Sanderson E, Glymour MM, Holmes MV, et al. Mendelian randomization. *Nat Rev Methods Primers* 2022; 2, 1-21. doi:10.1038/s43586-021-00092-5.

Chen L, Peters JE, Prins B, et al. Systematic Mendelian randomization using the
human plasma proteome to discover potential therapeutic targets for stroke. *Nat Commun* 2022;13:1-14. doi:10.1038/s41467-022-33675-1.

- 309 8 Yoshiji S, Butler-Laporte G, Lu T, et al. Proteome-wide Mendelian randomization
 310 implicates nephronectin as an actionable mediator of the effect of obesity on
 311 COVID-19 severity. *Nat Metab* 2023;5:248-64. doi:10.1038/s42255-023-00742-w.
- 9 Nakanishi T, Cerani A, Forgetta V, et al. Genetically increased circulating FUT3
 level leads to reduced risk of idiopathic pulmonary fibrosis: A Mendelian
 randomisation study. *Eur Respir J* 2022;59. doi:10.1183/13993003.03979-2020.
- 10 King EA, Wade Davis J, Degner JF. Are drug targets with genetic support twice
 as likely to be approved? Revised estimates of the impact of genetic support for drug
 mechanisms on the probability of drug approval. *PLoS Genet* 2019;15:1-20.
 doi:10.1371/journal.pgen.1008489.
- 319 11 Ochoa D, Karim M, Ghoussaini M, et al. Human genetics evidence supports
 320 two-thirds of the 2021 FDA-approved drugs. *Nat Rev Drug Discov* 2022;21:551.
 321 doi:10.1038/d41573-022-00120-3.
- Yoshiji S, Lu TY, Butler-Laporte G, et al, COL6A3-derived endotrophin mediates
 the effect of obesity on coronary artery disease:an integrative proteogenomics analysis. *medRxiv* 2023. doi: 10.1101/2023.04.19.23288706.
- 13 Li SF & Gong MJ. Therapeutic targets for haemorrhoidal disease: proteome-wide
 Mendelian randomisation and colocalization analyses. *medRxiv* 2023.

doi:10.1101/2023.06.19.23291373.

328 14 Hemani G, Zheng J, Elsworth B, et al. The MR-base platform supports systematic

- 329 causal inference across the human phenome. *Elife* 2018;7:1-29.
 330 doi:10.7554/eLife.34408.
- 15 Giambartolomei C, Vukcevic D, Schadt EE, et al. Bayesian Test for
 Colocalisation between Pairs of Genetic Association Studies Using Summary
 Statistics. *PLoS Genet* 2014;10. doi:10.1371/journal.pgen.1004383.
- 16 Hong Y, Kim HJ, Park S, et al. Single Cell Analysis of Human Thyroid Reveals
- the Transcriptional Signatures of Aging. *Endocrinol* (United States) 2023;164:1-12.
 doi:10.1210/endocr/bqad029.
- 17 Carter AR, Gill D, Davies NM, et al. Understanding the consequences of
 education inequality on cardiovascular disease: Mendelian randomisation study. *BMJ*2019;365:1-12. doi:10.1136/bmj.11855.
- 18 Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study
 identifies IL23R as an inflammatory bowel disease gene. *Science* 2006;314:1461-3.
 doi:10.1126/science.1135245.
- 19 Burton PR, Clayton DG, Cardon LR, et al. Association scan of 14,500
 nonsynonymous SNPs in four diseases identifies autoimmunity variants. *Nat Genet*2007;39:1329-1337. doi: 10.1038/ng.2007.17.
- 20 Kim MI. Hypothyroidism in Older Adults. [Updated 2020 Jul 14]. In: Feingold KR,
- 347 Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA):
- 348MDText.com,Inc.;2000-.Availablefrom:349https://www.ncbi.nlm.nih.gov/books/NBK279005/.
- 21 Zhang Y, Zhao M, Guo P, et al. Mendelian randomisation highlights
 hypothyroidism as a causal determinant of idiopathic pulmonary fibrosis. *eBioMedicine* 2021;73:103669. doi:10.1016/j.ebiom.2021.103669.
- 22 Allen RJ, Guillen-Guio B, Oldham JM, et al. Genome-Wide Association Study of
 Susceptibility to Idiopathic Pulmonary Fibrosis. *Thorax* 2022; 77(8): 829-833. doi:
 10.1136/thoraxjnl-2021-218577.
- 356

357 Figure Legends

Figure 1 Mendelian randomisation and colocalization results. (A) A diagram 358 depicting the Mendelian randomization principle and procedure filtering for MR 359 results. LOOA, leave-one-out analysis. (B) Shared the associations between 146 360 causative plasma proteins (related with at least one clinical trait) and 18 clinical traits 361 from MR analysis. For visualizing, only MR results showing no pleiotropy 362 (MR-Egger, *p*-value>0.5), no heterogeneity ($I^2 < 0.5$), and true causality direction 363 364 (Steiger test, p-value<0.05) were included. (C) The two mathematical models of genetic colocalization, causation, and colocalization, as well as LD confounding. (D) 365 Scanning for colocalization evidence of causative plasma proteins with outcomes. The 366 size of the circle represents the posterior probability for H4, and the color of the circle 367 represents the classification of the evidence. Red indicates high evidence for 368 colocalization (PH4>0.8); yellow indicates medium evidence for colocalization 369 (PH4>0.7); and green and black indicate moderate evidence for colocalization 370 (PH4<0.7). (E) The locus-compare scatter plot for the CRAT, LYPLAL1, and THBS3 371 372 association signals. The findings of colocalization analyses for CRAT (left), LYPLAL1 (center), and THBS3 (right) are shown. The marked SNP represents the 373 genetic variants used for the MR analysis. 374

375

376 Figure 2 Follow-up analyses for causal proteins associated with hypothyroidism.

(A) The locus-compare scatter plot compares the quantitative trait loci (pQTL) of 377 CA12 and the GWAS of hypothyroidism. (B) CA12 expression profile in human 378 tissues in GTEx v8 (https://gtexportal.org/). CA12 expression levels were displayed 379 on a log transcript per thousand plus one (TPM+1) scale. (C) CA12 expression 380 patterns in human thyroid tissues from thyroidectomy patients (GSE182416, 381 accessible at https://www.ncbi.nlm.nih.gov/geo/). NK cells: natural killer cells; SMCs: 382 smooth muscle cells. (D) A dot-plot revealing the expression of CA12 in epithelial 383 cells and fibroblasts in children and adults. (E) Forest plots for the effect of three 384 selected proteins on IPF. (F) Mediation effects of IRF3 on IPF via hypothyroidism. 385 For the effect of IRF3 on IPF mediated by hypothyroidism, the product of coefficients 386

- 387 method calculates the proportion mediated by multiplying BIRF3-to-hypothyroidism and
- 388 $\beta_{hypothyroidism-to-IPF}$ and subsequently dividing it by $\beta_{IRF3-to-IPF}$, where $\beta_{IRF3-to-hypothyroidism}$ is
- 389 the effect of IRF3 on hypothyroidism, $\beta_{hypothyroidism-to-IPF}$ is the effect of hypothyroidism
- 390 on IPF, and $\beta_{IRF3-to-IPF}$ is the total effect of IRF3 on IPF.
- 391
- 392 Supplementary Table 1 The summary statistics obtained in this study.





